Skip to main content
Erschienen in: International Journal of Hematology 3/2023

19.04.2023 | Case Report

Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review

verfasst von: Taro Fukuta, Hideki Muramatsu, Daiki Yamashita, Daichi Sajiki, Ryo Maemura, Yusuke Tsumura, Ayako Yamamori, Masayuki Imaya, Manabu Wakamatsu, Eri Nishikawa, Kotaro Narita, Shinsuke Kataoka, Rieko Taniguchi, Atsushi Narita, Nobuhiro Nishio, Yoshiyuki Takahashi

Erschienen in: International Journal of Hematology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Acute graft-versus-host disease (aGVHD) is a challenging complication of allogeneic hematopoietic stem cell transplantation, and alternative therapies for patients showing inadequate response to steroids are limited. Vedolizumab, an anti-α4β7 integrin antibody widely used for treating inflammatory bowel diseases, has recently been studied in adult patients with steroid-refractory intestinal aGVHD. However, few studies have examined its safety and effectiveness in pediatric patients with intestinal aGVHD. We report the case of a male patient with intestinal late-onset aGVHD treated with vedolizumab. He underwent allogeneic cord blood transplantation for warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome and developed intestinal late-onset aGVHD 31 months after transplantation. The patient was refractory to steroids; however, vedolizumab was initiated 43 months after transplantation (at the age of 7 years) and the symptoms of intestinal aGVHD were alleviated. Additionally, favorable endoscopic findings were observed, such as reduction of erosion and regenerative epithelial growth. We also evaluated the efficacy of vedolizumab in 10 patients with intestinal aGVHD (9 from the literature review and the present case). Six patients (60%) showed an objective response to vedolizumab. No serious adverse events were observed in any patients. Vedolizumab is a potential treatment option for steroid-refractory intestinal aGVHD in pediatric patients.
Literatur
1.
Zurück zum Zitat Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft-versus-host disease: a comprehensive review. Anticancer Res. 2017;37:1547–55.CrossRefPubMed Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft-versus-host disease: a comprehensive review. Anticancer Res. 2017;37:1547–55.CrossRefPubMed
2.
Zurück zum Zitat Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, et al. Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant. 2019;25:720–7.CrossRefPubMed Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, et al. Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant. 2019;25:720–7.CrossRefPubMed
3.
Zurück zum Zitat Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front Cell Dev Biol. 2021;9: 612830.CrossRefPubMedPubMedCentral Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front Cell Dev Biol. 2021;9: 612830.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chen Y-B, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, et al. Up-regulation of α4β7 integrin on peripheral T-cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1066–76.CrossRefPubMedPubMedCentral Chen Y-B, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, et al. Up-regulation of α4β7 integrin on peripheral T-cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1066–76.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Isshiki K, Kamiya T, Endo A, Okamoto K, Osumi T, Kawai T, et al. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease. Int J Hematol. 2022;115:590–4.CrossRefPubMed Isshiki K, Kamiya T, Endo A, Okamoto K, Osumi T, Kawai T, et al. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease. Int J Hematol. 2022;115:590–4.CrossRefPubMed
6.
Zurück zum Zitat Pai V, Abu-Arja R, Auletta JJ, Rangarajan HG. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient. Pediatr Blood Cancer Pediatr Blood Cancer. 2020;67: e28298.PubMed Pai V, Abu-Arja R, Auletta JJ, Rangarajan HG. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient. Pediatr Blood Cancer Pediatr Blood Cancer. 2020;67: e28298.PubMed
7.
Zurück zum Zitat Ibrahimova A, Davies SM, Lane A, Jordan MB, Lake K, Litts B, et al. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease. Pediatr Blood Cancer. 2021;68: e28968.CrossRefPubMed Ibrahimova A, Davies SM, Lane A, Jordan MB, Lake K, Litts B, et al. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease. Pediatr Blood Cancer. 2021;68: e28968.CrossRefPubMed
8.
Zurück zum Zitat Rosa M, Jarmoliński T, Miśkiewicz-Migoń I, Liszka K, Miśkiewicz-Bujna J, Panasiuk A, et al. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: a single-center pediatric series. Adv Clin Exp Med. 2022;31:345–50.CrossRefPubMed Rosa M, Jarmoliński T, Miśkiewicz-Migoń I, Liszka K, Miśkiewicz-Bujna J, Panasiuk A, et al. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: a single-center pediatric series. Adv Clin Exp Med. 2022;31:345–50.CrossRefPubMed
9.
Zurück zum Zitat Hughes TE, Stansfield L, Kumar P, Worthy TY, Tian X, Childs RW. A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. Bone Marrow Transplant. 2020;55:1085–92.CrossRefPubMedPubMedCentral Hughes TE, Stansfield L, Kumar P, Worthy TY, Tian X, Childs RW. A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. Bone Marrow Transplant. 2020;55:1085–92.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN. J Crohn’s Colitis. 2017;11:1230–7.CrossRef Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN. J Crohn’s Colitis. 2017;11:1230–7.CrossRef
Metadaten
Titel
Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review
verfasst von
Taro Fukuta
Hideki Muramatsu
Daiki Yamashita
Daichi Sajiki
Ryo Maemura
Yusuke Tsumura
Ayako Yamamori
Masayuki Imaya
Manabu Wakamatsu
Eri Nishikawa
Kotaro Narita
Shinsuke Kataoka
Rieko Taniguchi
Atsushi Narita
Nobuhiro Nishio
Yoshiyuki Takahashi
Publikationsdatum
19.04.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 3/2023
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03590-2

Weitere Artikel der Ausgabe 3/2023

International Journal of Hematology 3/2023 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.